Of note, monitoring of electronic patient−reported outcomes (ePROs) under chemotherapy for various solid tumors was associated with significantly longer survival in a pivotal study, and could therefore represent a cost-efficient alternative method to improve care of ALK+ NSCLC patients, since quality of life can fluctuate under treatment with TKI, as well (36, 37). Here, ALK is linked to non-small cell lung carcinoma.